Practice
Featured experience
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Durational Capital Management strategic investment in Garage Beer
We are advising Durational Capital Management on the transaction
Arcos Dorados renewal of long-term master franchise agreement with McDonald’s
We advised Arcos Dorados on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Rocket Companies $1.8 billion IPO and NYSE listing
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering by Rocket…
Rackspace Technology $703.5 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $703.5 million initial public…
Clarivate $6.8 billion combination with CPA Global
Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock…
Nurix Therapeutics $209 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of…
Permira Funds investment in EF Education First’s EF Kids & Teens business
Davis Polk is advising EF Education First in connection with the proposed investment by Permira Funds in EF Kids & Teens…
Jamf Holding $538.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $538.2 million initial public…
Berkeley Lights $204.9 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of…
Google investment in Reliance Industries’ Jio Platforms unit
Davis Polk is advising Reliance Industries Limited and Jio Platforms Limited in connection with binding agreements entered…
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…